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Recent work from others and us revealed interactions
between the Sin3/HDAC complex, the H3K4me3 demethylase
KDM5A, GATAD1, and EMSY. Here, we characterize the
EMSY/KDM5A/SIN3B complex in detail by quantitative inter-
action proteomics and ChIP-sequencing. We identify a novel
substoichiometric interactor of the complex, transcription fac-
tor ZNF131, which recruits EMSY to a large number of active,
H3K4me3 marked promoters. Interestingly, using an EMSY
knock-out line and subsequent rescue experiments, we show
that EMSY is in most cases positively correlated with transcrip-
tional activity of its target genes and stimulates cell prolifera-
tion. Finally, by immunohistochemical staining of primary
breast tissue microarrays we find that EMSY/KDM5A/SIN3B
complex subunits are frequently overexpressed in primary
breast cancer cases in a correlative manner. Taken together,
these data open venues for exploring the possibility that spo-
radic breast cancer patients with EMSY amplification might
benefit from epigenetic combination therapy targeting both the
KDM5A demethylase and histone deacetylases.
In the eukaryotic nucleus, DNA is condensed in the form of
chromatin. Chromatin is repressive to processes that require
access to the DNA. Chromatin accessibility can be regulated in
multiple ways, viz. by ATP-dependent chromatin remodeling
and post-translational modifications of core histones. Further-
more, the DNA itself can also be modified. A large number of
post-translational modifications on core histones have been
identified and characterized, including lysine acetylation and
lysine methylation. Some of these modifications are associated
with active transcription, whereas others are repressive to tran-
scription. The most studied post-translational modifications
on core histones are trimethylations of lysine residues, of which
several are known to occur on theN terminus of one of the four
core histones,H3. Twoof these (H3K4me3 andH3K36me3) are
linked to active promoters and gene bodies, respectively, and a
third one (H3K27me3) is associated with gene silencing (1).
The biology of each of these modifications is believed to be at
least partially determined by proteins, so-called chromatin
readers, that can specifically recognize these chromatin marks.
Lysine trimethylation reader domains include the PHD finger,
the chromodomain, and the Tudor domain (2).
Previously, we used quantitative mass spectrometry-based
proteomics to identify a large number of chromatin readers for
lysine trimethylation sites on histone H3 and H4 (3). In that
study, we identified a number of previously unrelated proteins,
includingGATAD1, EMSY, KDM5A, and SIN3B, as readers for
H3K4me3. Subsequent experiments revealed that these pro-
teins may in fact be part of a novel protein complex. Similar
observations in Drosophila were also reported by others (4).
EMSY was originally reported as a transcriptional repressor
and breast cancer-associated protein that interacts with the
BRCA2 protein (5). KDM5A is a histone lysine demethylase for
H3K4me3 (6) containing a PHD finger that directly binds
H3K4me3 (7). SIN3B is part of a complex containing histone
deacetylase activity (8). These proteins and their associated
enzymatic activities therefore suggest that the EMSY complex
is a transcriptional repressor.
Here, we applied state-of-the-art quantitative mass spec-
trometry and ChIP sequencing approaches to characterize the
EMSY protein complex and its genome-wide binding profile.
Our experiments revealed a striking association between EMSY
and H3K4me3-marked, active promoters. Using a CRISPR/
Cas9-based knock-out line and rescue experiments we show
that in most cases, EMSY expression is positively correlated
with expression of its target genes and stimulates cell prolifer-
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ation. Furthermore, we identify a novel interactor of the EMSY
complex, ZNF131, which recruits EMSY to a subset of its
genome-wide targets. Finally, we used immunohistochemistry
on primary breast cancer tissues, which revealed a striking
expression correlation between EMSY complex subunits, sug-
gesting a functional and pathological link between these pro-
teins in relation to breast cancer.
Experimental Procedures
Generating Stable Cell Lines and Cell Culture—To generate
mammalian cells expressing proteins of the EMSY/KDM5A
complex at near endogenous levels bacterial artificial chromo-
somes containing EMSY, GATAD1, PHF12, or KDM5A,
respectively were obtained from the BACPAC Resources Cen-
ter and a GFP cassette was inserted as a C-terminal in-frame
fusion usingBAC recombineering (9).HeLa orMCF7 cells were
transfected with the recombineered BAC using Lipofectamine
2000 or PEImax (for EMSY) and selected with 400 g/ml gene-
ticin (G418).
Expression of the recombineered ZNF131 BAC inHeLa cells
proved unsuccessful hence a full-length mouse ZNF131 con-
struct that was a gift from Juliet Daniel was cloned into the
plasmid pBabePuro-C-GFP by gateway cloning that was used
to generate retrovirus particles using the Phoenix ecotropic
packaging cells. Finally MCF7 cells were transduced with this
virus and 24 h after infection, subjected to 1 g/ml puromycin
selection. Monoclonals were isolated, and cell lines were
propagated.
Short hairpin knockdown of ZNF131 in the EMSY GFP
expressing HeLa cells was mediated by lentiviral transduction.
A set of 5 short hairpins purchased from Sigma were trans-
fected into COS7 cells in combination with lentiviral packaging
vectors using PEImax. After 24 h, virus generated into the
medium was aspirated, filtered, and concentrated. The target
cells (EMSY GFP HeLa) were transduced with the virus in
the presence of polybrene. shRNA integrated cells were sub-
jected to puromycin selection, 24 h after transduction. Single
cells were grown into monoclonals and the knockdown sta-
tus was assessed by RT-qPCR and Western blotting (Anti-
ZNF131, mouse polyclonal #H0000 7690-B0IP, Abnova). The
monoclonals selected for this study were shZNF131#1
(TRCN0000254328) and shZNF131#2 (TRCN0000254331).
CRISPR Knock-out of EMSY—The knock-out of EMSY was
created using CRISPR-Cas9 system. Ensembl transcript se-
quence of isoform C11orf30-001 (ENST00000529032) was
used as canonical isoform. The guides were designed against an
exon common to all isoforms, i.e. exon3. The oligos (Biolegio)
encoding guide RNAs for inducing a double strand break
(DSB)6 in the genome were designed using the Zhang labo-
ratory genome engineering website CRISPR tool. Guide
sequence EMSY-DSB-G2-F: AACGCCACCGTGCTGAAGTT
and EMSY-DSB-G2-R: AACTTCAGCACGGTGGCGTTwere
used for cloning. The guides were cloned into pSpCas9(BB)-
2A-Puro (PX459) vector (10). The resulting constructs were
sequence verified and used for transfection. The constructs
were transfected into HeLa cells using Lipofectamine
LTX&PLUS (Invitrogen). The transfected cells were grown for
2 days and subsequently selected with puromycin for a brief
period of 2 days. The surviving cells were clonal diluted into 96
well plates to generate clonal populations from single cells.
Genomic DNA from the clonal populations was harvested by
using a genomicDNA isolation kit (Invitrogen). TheDSB target
region was amplified using primers EMSY-forward: GCCTGC-
TTGGCAGAGTTCTAT and EMSY-reverse: GACTCAGGA-
ATCTGCTACACAA. The amplified regions were Sanger
sequenced, and resulting sequences were matched to the wild
type transcript. Clones with deletions were tested for knock-
outs using Western blots (Anti-EMSY, rabbit polyclonal,
#A300-253A, Bethyl Laboratories). Re-expression of EMSY-
GFP in the EMSYCRISPRknock-out lineswas performedusing
an EMSY-GFP (EX-E2426-M29) from Genecoepia (EX-NEG-
M29 was the empty control vector).
GFP Purifications and Label-free Quantitative Mass Spec-
trometry—Nuclear extract isolation and GFP pull-downs fol-
lowed by sample preparation for mass spectrometry and data
analysis was performed as described in Ref. 11. Briefly, nuclear
extracts obtained from GFP-tagged protein-expressing and
wild-type cells were subjected toGFP-affinity pull-downs. 1mg
of nuclear extract was used for each pull-down and incubated
withGFP chromotek beads for 90min, and then the beads were
washed and subjected to on-bead trypsin digestion. The tryptic
peptides were eluted and applied to online nano LC-MS/MS.
Raw data were analyzed by Max Quant and t test-based statis-
tics was applied on LFQ for interactor identification. iBAQ
algorithm was used for determining the stoichiometry of the
identified complexes.
Cell Proliferation Assays—Four different cell lines were used
for the cell proliferation assays shown in Fig. 4. WT Hela cells
with empty vector control and EMSY knock-out cells (CRISPR-
mediated knock-out, see Fig. 4A) were used in Fig. 4, B and C.
Furthermore, EMSY knock-out cells were stably transfected
(PEI transfection reagent, G418 selection) with an EMSY-GFP
construct or an empty vector control (Fig. 4,D and E). The four
resulting cell lines were trypsinized into single cells, counted,
and 250 or 500 cells were seeded in duplicates in 24-well plates
containing DMEM with 10% FBS. The cells were allowed to
grow into visible colonies, and 10days after seeding the colonies
were fixed inmethanol and stainedwith crystal violet. Thewells
were scanned to obtain representative images, and the number
of colonies in each well was counted. This was expressed as %
colonies survival over the initial number of cells seeded.
DNA and GST Pull-downs—DNA pull-downs were per-
formed mainly as described in Ref. 12. For each DNA pull-
down, 2.5 g of biotinylated oligos containing 3 repeats of the
DNA sequence with interspersed spacer (CONS1: GTCGCG,
CONS2: GTCGCA, MUT: GCAGCG, SCR:GGGCCT) was
immobilized on 25 l of DynabeadsMyOne C1 (Invitrogen) by
incubating for 1 h at room temperature in a total volume of
350l of DNA binding buffer (1 MNaCl, 10mMTris-HCl, pH
8 , 1 mM EDTA, pH 8, and 0.05% Nonidet P-40). Beads con-
taining immobilized DNA were then incubated with GST-
lysates expressing the recombinant ZNF131 domains in a
total volume of 600 l of protein binding buffer (50 mM
6 The abbreviations used are: DSB, double strand break; LFQ, label-free quan-
titation; ChIP, chromatin immunoprecipitation.
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Tris-HCl pH 8, 150 mM NaCl, 1 mM DTT, 0.25% Nonidet
P-40, and Complete protease inhibitors (Roche, EDTA-
free)) in the presence of 10 g of poly-dAdT for 2 h at 4 °C.
Baits were then washed three times with 0.5 ml of protein
binding buffer after which protein bound to the beads was
eluted and analyzed by Western blotting.
For GST pull-downs, recombinant GST-ZNF131 fusion pro-
teins were expressed in bacteria and lysates weremade. Soluble
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FIGURE 1. Characterization of EMSY/KDM5A/SIN3B complex. A, schematic representation of the experimental setup. B, heatmap showing the average LFQ
intensities of the EMSY interactors (indicated to the left) inGFPpurifications of different EMSY complex subunits (indicatedon top). In eachof thesepull-downs,
a set of largely overlapping interactors is detected, indicating that these proteins form a stable complex. C, co-immunoprecipitation and Western blotting
experiments to validate the interactions thatweredetectedby label freemass spectrometry.WT, wild-typeextract. SinceGATAD1andTBPare smaller proteins,
the GFP probing was done on two different blots to detect the higher (top GFP blot) and smaller (bottom GFP blot) molecular weight proteins, respectively. D,
ZNF131 enriches GFP-EMSY from HeLa nuclear extracts. GST-tagged ZNF131 fusion proteins were immobilized on glutathione agarose beads and subse-
quently used for pull-downs in nuclear extracts from HeLa cells expressing GFP-tagged EMSY and probed with GFP antibody. These experiments clearly
revealed that the ZNF131 POZ domain is both necessary and sufficient to mediate a direct interaction with EMSY or an EMSY-interacting protein.
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GST-taggedZNF131 fusion proteinswere then immobilized on
glutathione-agarose beads and subsequently used for binding
proteins from nuclear extracts of HeLa cells expressing GFP-
taggedEMSY.The boundproteinswere eluted off theGAbeads
and analyzed by Western blotting by probing with a GFP
antibody.
ChIP-qPCR and ChIP-Seq—HeLa Kyoto wild type (WT),
HeLa EMSY GFP, and HeLa EMSY GFP with knockdown of
ZNF131 were seeded in 15-cm dishes and 24 h later were form-
aldehyde cross-linked for 10min. Chromatin obtained from the
cells after sonication was subjected to overnight IP using GFP
antibody (Abcam, ab290) followed by extensive washes and
decross-linking. DNA was purified using the Qiagen PCR
clean-up kit and the bound DNA was analyzed by qPCR using
the desired primers. ChIP-Seq was carried out by conventional
ChIP followed by end repair of 15 ng (for protein-GFP fusions)
or 30 ng (for the histone modifications) enriched DNA as mea-
sured by Qubit fluorometer using the Quant-iT dsDNA HS
Assay Kit from (Invitrogen, Q32851). Adaptors were ligated to
DNA fragments, which were subsequently size selected (300
base pair (bp). The adaptor-modified DNA fragments were
subjected to limited PCR amplification (14 cycles) and quality
control was made by qPCR (primers sequences are available
upon request), as well as by running the PCR products on a
Bioanalyzer (Bio-Rad). Finally, cluster generation and sequenc-
ing-by-synthesis (36 bp) was performed using the Illumina
Genome Analyzer IIx (GAIIx) according to standard protocols
of the manufacturer (Illumina). The image files generated by
theGenomeAnalyzerwere processed to extractDNA sequence
data. Sequences were aligned to the human reference genome
(GRCh37/hg19, Feb 2009) with Burrows-Wheeler Aligner1
(bwa,v0.5.9-r16) allowing one mismatch. Uniquely aligned
reads were converted to BED format. The total number of
sequenced fragments andmapped fragments are shown in sup-
plemental Table S5. All ChIP and input samples were normal-
ized randomly to the same number of reads (10543138). Fur-
thermore, reads were directionally extended to 300 bp, and for
each base pair in the genome the number of overlapping
sequence reads was determined and averaged over a 10-bpwin-
dow to create a Wiggle (WIG) file to visualize the data in the
University of California Santa Cruz (UCSC) Genome Browser.
PeakDetection—Identification of the binding sites (peak call-
ing) was performed using MACS (13) (version 2.0.9 20111102,
tag:alpha) with parameters: -g 2.7e9; -m 10,30; -q 0.05.
Genomic regions overlapping to the peaks in the negative con-
trol (GFP ChIP-Seq on wild type HeLa cells) were filtered out.
Genomic annotation was carried out with Hypergeometric
Optimization of Motif EnRichment (HOMER, software v4.2).
The tool annotatePeaks was used with parameters by default
and defined in the help. A gtf file from GENCODE project
based on release 15 (GRCh37/hg19) was used for annotations;
the latter included whether a segment is in the TSS/promoter,
TTS, exon, 5 UTR exon, 3 UTR exon, intron, or is intergenic.
Since some annotations overlap, the following priority was
assigned: TSS/promoter (from 1 kb to 100 bp), TTS (from
100 bp to 1 kb), CDS exon, 5 UTR exon, 3 UTR exon,
intron, intergenic. The heatmaps and distribution plot repre-
sentations were carried out with R package v2.14.1, SeqMiner
v1.3.3e (14) and fluff.7 Heatmaps represent summed reads in
100 bp sliding windows flanking 5 kb to the EMSY- or
H3K4me3-bound sites. The overlap between EMSY- and
GATAD1-binding sites was calculated with IntervalStats v1.01
(16) using the EMSY-binding sites as reference file. The p value
applied for overlapping was 0.05.
Pathway Enrichment Analysis—To identify the biological
relevant pathways of EMSY-targeted genes we used the func-
tional annotation tool available in the DAVID bioinformatics
resources v6.7 (17). DAVID identifies the most relevant path-
ways from the Kyoto Encyclopedia of Genes and Genomes
(KEGG) (18), REACTOME (19) and Gene Ontology (20) data-
7 G. Georgiou and S. J. van Heeringen, personal communication.
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FIGURE 2. Stoichiometry of the EMSY/KDM5A/SIN3B complex. A and B,
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bases. Pathways with a Benjamini-Hochberg corrected p value
lower than 0.1 were considered significant.
Motif Enrichment Analysis—The ZNF131 DNA-binding
motifs were obtained fromDonaldson et al. (21).We calculated
the frequency of themotif in the EMSY-binding sites. To deter-
mine that the frequency observed is not random chance, we
generated 100 simulations of random genomic sequences
adjusted by the number and length of it for EMSY-binding sites
defined with MACS (see above). For this purpose, we used the
subcommands shuffle and getfasta included in bedtools v2.18.2.
Further, we tested the differences with the Fisher’s exact test (p
value  0.004) and generated the distribution plots in R pack-
age v2.14.1.
mRNA Expression Analysis—500 ng of RNA extracted from
mammalian cells using the QIAgen RNA extraction kit was
used for cDNA synthesis using random primers and Super-
script II from the Invitrogen first-strand cDNA synthesis kit.
mRNA expression of EMSY and the EMSY target genes was
analyzed by qPCR using the primers designed for EMSY and
EMSY target genes and the values obtained were normalized
over actin expression. Gene expression data of 6791 tumor
samples analyzed according to the RnaSeqV2 pipeline was
downloaded fromTheCancerGenomeAtlas (TCGA) data por-
tal at 14-05-2014 to investigate the co-regulation of EMSY sub-
units across different cancers.
Patient Material—Tissue samples of invasive breast cancer
patients were collected between November 2004 and Septem-
ber 2009 at the Department of Pathology of the University
Medical Centre in Utrecht (UMCU), The Netherlands. This
study selected 103 tissue samples from this consecutive series.
According to the Dutch Federation of Medical Scientific Soci-
eties (the FEDERA), use of redundant tissue for research pur-
poses does not require informed consent, if the patients are
offered the possibilities to refuse this (“opting out” system) and
material has been used anonymously or coded. In the UMC
Utrecht, all patients are informed that research may happen
with their redundant tissue, and are offered to opt out. No
material of patients that have opted out was used in the present
study, and all materials were used anonymously. The research
protocol for this study was approved by the Scientific Advisory
Counsel of the UMCUtrecht Biobank. Grading was performed
according to the Nottingham modification of Bloom-Richard-
son system, and mitoses were counted according to a strict
protocol as before to arrive at the mitotic activity index (MAI)
(23).
Immunohistochemistry—After deparaffinization and rehy-
dration, antigen retrieval was performed using citrate buffer for
EMSY, SIN3B, and ZNF131, and EDTA buffer for GATAD1,
KDM5A, at boiling temperature for 20min. A cooling period of
30min preceded the incubation of the slides with protein block
for EMSY, GATAD1, and KDM5A (Novolink Max Polymer
detection system, ready to use, Novocastra Laboratories Ltd,
Newcastle Upon Tyne, UK) for 5 min at room temperature.
Incubation of the slides with the EMSY antibody (rabbit poly-
clonal, #A300-253A, Bethyl Laboratories) was done at a dilu-
tion of 1:100, for KDM5A (rabbit monoclonal, # 3876S, Cell
Signaling) at a dilution of 1:50 and for GATAD1 (mouse
monoclonal, # sc-81092, Santa Cruz Biotechnology) at a
dilution of 1:50, for 60 min at room temperature. For detec-
tion, a polymer (Novolink Max Polymer detection system,
ready to use) was used. For ZNF131 (mouse polyclonal, #
H0000 7690-B0IP, Abnova) and SIN3B (in-house), the slides
were incubated with primary antibodies at a dilution of 1:50
for both of them for 60 min at room temperature. For detec-
tion a poly HRP anti-mouse/rabbit/rat IgG (Brightvision,
ready to use, ImmunoLogic, Duiven, Netherlands) was used.
All slides were developed with diaminobenzidine (5 min for
Novolink protocol and 10 min for Brightvision) followed
by hematoxylin counterstaining. Before the slides were
mounted all sections were dehydrated in alcohol and xylene.
Positive controls were used throughout; negative controls
were obtained by omission of the primary antibodies from
the staining procedure.
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GFP ChIP signal in identified EMSY peaks (top panel) and EMSY-GFP ChIP signal versus GFP ChIP signal in WT HeLa cells (bottom panel).
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Scoring of immunohistochemistry was performed by one
observer (PJvD). For EMSY, KDM5A, SIN3B, ZNF131,
GATAD1, the percentage of positively stained nuclei was esti-
mated, furthermore cytoplasmic expression of EMSY was also
scored in a scale of 0, 1, 2, and 3. In the statistical analysis we
used the product of the EMSY nuclear and cytoplasmic scoring
data. Associations among staining were tested by Chi-square
analysis.
Results
Recently, we described protein-protein interactions between
the H3K4me3 demethylase KDM5A, the protein EMSY,
GATAD1, and components of the SIN3/HDAC complex in
HeLa cells (3). To further characterize these interactions, we
generated BAC-GFP transgenic HeLa cell lines for EMSY,
KDM5A, PHF12, and GATAD1. Nuclear extracts derived from
these cells were subjected to single affinity GFP purifications
coupled to label-free quantitative mass spectrometry (Fig. 1A).
Similar, largely overlapping interactions were observed in each
case, indicating that these proteins form a large multi-subunit
protein complex (Fig. 1B, supplemental Table S1, for KDM5A
data not shown). This protein complex resembles the recently
characterized Drosophila Lid/Sin3 complex (4), as well as the
SIN3B uniCORE complex reported previously (24). However,
neither BRCA2 or HP1 that were initially reported as EMSY
interactors (5) were found in our experiments, which we
assume is due to differences in experimental systems. Given the
reported link between EMSY and breast cancer, we also puri-
fied EMSY-GFP from a breast cancer cell line, MCF7 (data not
shown) and observed interactions almost identical to those
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observed in HeLa cells. Given the very low expression of the
EMSY-GFP BAC inMCF7 cells, we used HeLa cells for most of
our subsequent analyses.
Interestingly, a DNA-binding zinc finger protein, ZNF131,
was consistently identified in the affinity purifications, indicat-
ing that this protein may be a novel EMSY/KDM5A interactor.
To validate this interaction between ZNF131 and EMSY/
KDM5A we generated a stable MCF7 cell line expressing
ZNF131-GFP at sub-endogenous levels. As shown in Fig. 1B,
EMSY/KDM5A components co-purified with GFP-ZNF131, as
well as some subunits of theMLL H3K4me3 methyltransferase
complex (MLL, DPY-30). We did not, however detect the pre-
viously reported ZNF131 interactor Kaiso (21). Nevertheless, a
number of other putative DNA-binding proteins were identi-
fied as interactors, including ZMYM1, ZBTB3, and ZNF281.
Some of these observed interactions were also validated using
Western blotting (Fig. 1C). ZNF131 contains a number of
domains, including an N-terminal POZ domain and five C-ter-
minal zinc fingers (21). The N-terminal POZ domain enriches
GFP-EMSY from HeLa nuclear extracts, indicating that this
domain interacts either directly with EMSY or plausibly via an
EMSY interacting protein (Fig. 1D).
iBAQ-based stoichiometry estimation of the detected inter-
actions revealed that the core EMSY complex consists of
GATAD1, PHF12, EMSY, RBBP4/7, MORF4L1/2, SIN3B,
KDM5A, and HDAC1/2 (Fig. 2A). Several subunits in the com-
plex, appear to be multimeric, including GATAD1, PHF12,
EMSY, and RBBP4/7. Western blotting also revealed that
EMSY-GFP co-purifies endogenous EMSY, thus providing fur-
ther evidence for multimerization (Fig. 1C, top panel). Further-
more, approximately equal amounts of endogenous EMSY
co-purifies with GFP-EMSY, illustrating that EMSY-GFP is
expressed at near-endogenous levels. ZNF131 and the other
zinc finger proteins are substoichiometric, the intensity of
ZNF131 being10% relative to the core subunits, for example.
Stoichiometry analysis of the GFP-ZNF131 pull-down revealed
that EMSY and MLL complex subunits as well as ZMYM1 are
the major ZNF131 interactors (Fig. 2B). Altogether, these
results establish a core EMSY interactome and in addition, a
number of putative DNA-binding, substoichiometric interac-
tors (Fig. 2C).
To gain further insights into the biology of the EMSY com-
plex, we performed ChIP-sequencing on EMSY-GFP cells. In
theHeLa genome, 3371 binding sites for EMSYwere identified,
the largemajority of which (73%) are close to transcription start
sites (Fig. 3, A and B, supplemental Table S2). Interestingly,
these EMSY peaks on promoters coincide with high levels of
H3K4me3 (profiled inWTHeLa cells) andGATAD1, for which
we performed ChIP-sequencing previously ((3), Fig. 3, C and
D). As shown in Fig. 3E, we observed a strong genome-wide
correlation between the GATAD1-GFP and EMSY-GFP signal
on identified EMSY peaks (median length 484 bp). This cor-
relation (R2 0.37; top panel) is three times stronger than one
would expect from just the increased DNA accessibility of
EMSY-bound promoters (R2 0.13; bottom panel), indicating
that the observed genome-wide association between EMSY and
GATAD1 represents true co-localization of the two proteins.
The genome-wide correlation between EMSY andH3K4me3 is
intriguing, given the presence of the H3K4me3 demethylase
KDM5A and histone deacetylases, in the EMSY complex.
H3K4me3 demethylase activity and histone deacetylation are
both enzymatic activities that are generally linked with gene
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repression. Apparently, in the context of the EMSY complex,
these activities are not strictly associated with stable gene
repression. In support of these observations, recent genome
wide profiling for histone deacetylases also revealed a correla-
tion with actively transcribed genes (25). To further investigate
the effects of the EMSY/KDM5A complex on target gene
expression, we generated an EMSY knock-out HeLa cell line
using CRISPR-Cas9 (Fig. 4A). We then analyzed expression of
12 EMSY target genes, as determined by ChIP-seq (supplemen-
tal Table S2), using qPCR. Interestingly, most of the analyzed
EMSY target genes showed reduced expression in the absence
of EMSY relative to the control cell line (Fig. 4B).We also tested
the proliferation capacity of the control and CRISPR knock-out
line using a colony formation assay (Fig. 4C), which revealed a
reduction in colony formation in the absence of EMSY, consis-
tent with reports in (26) and given its reported function as a
putative oncogene. To further substantiate these results we
conducted rescue experiments by re-expressing EMSY in the
CRISPR knock-out line. Re-expression of EMSY in the knock-
out line in most cases resulted in up-regulation of EMSY com-
plex target genes relative to a mock transfection (Fig. 4D). Fur-
thermore, increased proliferation capacity was observed (Fig.
4E). These observations are consistent with our ChIP-seq data,
which indicates a strong link between the EMSY/KDM5Acom-
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plex and genes related to cell proliferation and/or cell cycle
regulation (supplemental Table S3). Altogether, these results
imply that the EMSY/KDM5A complex is important for regu-
lating target gene expression rather than exclusive transcrip-
tional repression, however this may not be true for all target
genes. In addition, the presence of EMSY is important for cell
proliferation as also shown in Ref. 26.
Although we observed a strong genome-wide correlation
between the EMSY complex and H3K4me3, not all H3K4me3-
marked genes are bound by the EMSY complex (Fig. 5A). This
implies that other factors, such as DNA-binding proteins in the
complex, contribute to achieve genome-wide binding specific-
ity. An ISMARA analysis of the DNA sequences in the EMSY
peaks showed enrichment for theDNA-bindingmotifs ofNRF1
A
B
EMSY EMSY
GATAD1ZNF131
SIN3BKDM5A
FIGURE 7. Co-regulation of EMSY complex subunits in breast cancer. A, representative immunohistochemical staining images of a patient with positive
EMSY staining (left) and another case that stained negative for EMSY (right). B, case with positive EMSY staining in A was stained for other EMSY/KDM5A
complexmembers. ZNF131, GATAD1, and KDM5A correlated positively with the EMSY status whereas SIN3B correlated negatively. The example in A that was
negative for EMSY expression, was also negative for ZNF131, GATAD1, KDM5A, and SIN3B (data not shown), thus revealing a positive expression correlation
between the EMSY/KDM5A complex subunits in primary breast cancer.
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and ZNF335 (data not shown). Interestingly, both of these pro-
teins were found as interactors of the EMSY/KDM5A/SIN3B
complex in our study (Fig. 1B). However, the most prominent
putative DNA-binding protein in the EMSY complex, as
revealed by EMSY complex stoichiometry analyses, is ZNF131
(Fig. 2A). The DNA binding specificity of this protein has been
previously determined using the CAST approach (21). Interest-
ingly, 35% of the genome wide EMSY peaks contain a motif
which resembles this ZNF131 consensus binding site (Fig. 5B).
This implies that the ZNF131 protein may recruit the EMSY
complex to a subset of its genome wide targets. In support of
this, we confirmed that the recombinant zinc finger domain of
ZNF131 specifically binds to consensus DNA-binding sites
(GTCGCG and GGGCCT) that are enriched in the EMSY
ChIP-sequencing peaks (Fig. 5C). To investigate a potential role
for ZNF131 in recruiting the EMSY complex to target sites in
the genome, we generated a stable shRNA-based ZNF131
knock-down in the GFP-EMSY HeLa BAC line (Fig. 6A). This
cell line was subjected to GFP-based ChIP-sequencing. As
shown in Fig. 6, B and C, ZNF131 knock-down resulted in a
substantial loss of genome-wide EMSY binding (supplemental
Table S4). These observations were validated using ChIP-qPCR
(Fig. 6D). In summary, these results imply that the DNA-bind-
ing ZNF131 protein regulates recruitment of the EMSY com-
plex to a substantial subset of genome-wide target genes.
Previously, the EMSY protein was shown to be amplified in
sporadic breast cancer (5). While mining the EMSY ChIP-seq
data, we observed that the EMSY protein binds to the promoter
of a number of EMSY complex subunits, including KDM5A
(Fig. 9A), SIN3B and HDAC1 (data not shown). Given the fact
that EMSY expression is in most cases positively correlated
with expression of its target genes (Fig. 4B), this prompted us to
investigate a potential deregulation of EMSY complex subunits
in breast cancer. To this end, we performed immunohisto-
chemistry staining of primary breast tissue microarrays, com-
prising samples from 103 patients (Fig. 7). We started out with
a consecutive cohort of 103 breast cancer casesmostly of ductal
type with mild to aggressive morphology (grade 1–3). While
screening this cohort for the expression of themarkers of inter-
est we lost about 29 cases due to loss of tissue material. The
breast cancer patient cohort could be divided into two groups:
EMSY positive 51% (39/77) or negative 49% (38/77) breast can-
cer cases (see Fig. 7A for example staining). For ZNF131 and
neg pos p-value
Age <58 21 23
>58 18 18 0.554
Type Ductal 35 29
Ductal-lobular 1 4
Lobular 3 4
mucinous 0 1 0.322
Grade 1 3 3
2 10 12
3 25 23 0.876
ZNF131 neg 28 10
pos 9 28 0.000
GATAD1 neg 28 11
pos 10 27 0.000
KDM5A neg 25 12
pos 13 25 0.004
SIN3B neg 34 24
pos 5 14 0.015
EMSY product 
FIGURE 8. Table showing the statistical significance in the correlation
betweentheexpressionofEMSYandothercomplexmembers inprimary
breast cancer tissuemicroarrays.
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FIGURE 9. EMSY complex subunits are co-regulated across thousands of
tumor samples.A, snapshot from theUCSCgenomebrowser showing co-lo-
calization of EMSY-GFP andGATAD1-GFPon the KDM5Apromoter. GFPChIP-
seqonWTHeLa cells (control) is shown in red. B, histogram showinggenome-
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GATAD1 expression 51% (37/75 & 37/76) of the cases were
positive and 49% (38/75 & 37/75) were negative. Overexpres-
sion of KDM5A was seen in 51% (38/75) of the cases. Most of
the cases 75% (58/77)were SIN3Bnegative (see Fig. 7B for some
example staining). In summary, this data reveals that EMSY
overexpression in breast cancer is often accompanied by over-
expression of EMSY complex members (Fig. 8), viz. ZNF131 (p
value0.001), GATAD1 (p value0.001), KDM5A (0.004) and
SIN3B (0.015), suggesting a cooperative function in relation to
cancer. Investigating RNA-seq-based expression data for
EMSY complex subunits across thousands of tumor samples
from the TCGA Research Network further substantiates this
observed positive expression correlation between EMSY com-
plex subunits (Fig. 9).
Discussion
Here, we have shown that the EMSY/KDM5A complex
mainly binds to H3K4me3-marked, actively transcribed genes
in the mammalian genome. Given the enzymatic activities in
the complex, a H3K4me3 demethylase and histone deacety-
lases, these observations are somewhat surprising. However,
recent evidence suggests that histone deacetylase activity and
co-repressor complexes are not exclusively linked to gene
silencing but can also support active transcription (27). The
molecularmechanisms underlying this apparent biological ver-
satility are not clear yet. Mammalian transcription has been
suggested to involve cyclical waves of acetylation/methylation-
deacetylation/demethylation (25, 28) and the EMSY complex
may also be involved in this process. Especially our interactom-
ics data tempt to suggest that ZNF131 on one hand, via its
association with theMLL complex, could be involved in direct-
ing the recruitment of the chromatin writers to genomic loci
while on the other hand dictating the targeting of the EMSY/
KDM5A eraser complex. Further experiments using synchro-
nized cells and time-course experiments should shed further
light on this. It should also be noted that ChIP-sequencing pro-
vides correlative data and observed signals represent average
binding profiles obtained from thousands of asynchronous
cells. Nevertheless, EMSY knock-out/rescue experiments fur-
ther substantiated a positive link between the EMSY complex
and gene expression (Fig. 4,B andD). In contrast, a recent study
linked EMSY to transcriptional repression of a miRNA (26).
Our experiments also show that in a minority of cases, EMSY
expression is negatively correlated with target gene expression.
Further experiments are imperative to decipher the molecular
mechanisms of EMSY complex-mediated regulation of gene
expression.
ChIP-seq revealed that EMSY mainly binds to transcription
start sites and coinciding with H3K4me3. Importantly, knock-
down of ZNF131 resulted in a substantial reduction of EMSY
peaks in EMSY-GFP ChIP-seq experiments suggesting a
requirement for ZNF131 as a recruiting factor. However, in our
study, several DNA-binding proteins apart from ZNF131 viz.,
ZMYM1, ZBTB3, ZNF281, NRF1, and ZNF335 have also been
identified as EMSY and/or ZNF131 interacting proteins. Hence
it is plausible that some of these DNA-binding proteins may
also have a role in recruitment of the EMSY complex to its
genomic-binding sites. Consistent with this, we observed that
upon ZNF131 knockdown, EMSY recruitment to a subset of its
target genes is not affected (Fig. 6D).
Immunohistochemistry experiments on primary human
breast cancer cases revealed a striking co-regulation of EMSY/
KDM5Acomplexmembers in a subset of EMSY-positive breast
cancers, which further substantiates our proteomics data and
suggests that EMSY complex subunits may functionally coop-
erate in sporadic breast cancers which are characterized by
EMSY amplification. The presence of histone deacetylases,
HDAC1 and HDAC2, and a histone lysine demethylase,
KDM5A, in the EMSY complex is worth mentioning from a
clinical perspective. Histone deacetylase inhibitors are already
used in the clinic to treat a variety of malignancies (29), and our
data suggest that breast cancer patients that showEMSY ampli-
fication may benefit from treatment with histone deacetylase
inhibitors as well. Currently, efforts are also being made to
develop specific inhibitors targeting histone demethylases,
which are frequently deregulated in cancer (30). Combining
HDAC inhibitors with specific inhibitors targeting the KDM5A
demethylase may be an interesting epigenetic combination
therapy in sporadic breast cancers as well as other cancers that
show EMSY amplification. This is particularly relevant given
the fact theKDM5Ademethylase andhistone deacetylases have
been linked to drug resistance in cancer (31). Treatment of
cancers that display EMSY/KDM5A over-expression with
HDAC inhibitors and a KDM5A inhibitor might therefore
serve a dual purpose: counteracting EMSY/KDM5A/SIN3B
overexpression, thereby inhibiting cell proliferation, while at
the same time preventing cancer cell drug resistance.
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